Αρχική World News Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of... World News Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer Από Ogkologos - 29 Απριλίου, 2025 931 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Taking on the RAS Challenge 8 Οκτωβρίου, 2026 Breathing Amidst Uncertainty 5 Μαρτίου, 2021 Workout Wednesdays – Chest Exercises Part 1 10 Ιουνίου, 2020 Coping With Cancer Recurrence: My Perspective As Both a Patient and... 24 Ιανουαρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... COVID-19: “We’ve got so much on our plates”